Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* High-risk patients who have undergone successful PCI with at least one locally approved drug eluting stent discharged on DAPT with aspirin and ticagrelor of at least 3 months intended duration will be eligible for the TWILIGHT study.~* Enrollment into the study will require meeting at least one clinical inclusion, one angiographic inclusion and none of the exclusion criteria.~Clinical Inclusion Criteria:~* Adult patients ≥ 65 years of age~* Female gender~* Troponin Positive acute coronary syndrome~* Established vascular disease defined as previous MI, documented PAD or CAD/PAD revascularization~* Diabetes mellitus treated with medications (oral hypoglycemic, subcutaneous injection of insulin)~* Chronic kidney disease defined as an estimated glomerular filtration rate (eGFR) \< 60 ml/min/1.73m2 or creatinine clearance (CrCl) \< 60 ml/min~Angiographic Inclusion Criteria:~* Multivessel coronary artery disease~* Target lesion requiring total stent length \>30 mm~* Thrombotic target lesion(s)~* Bifurcation lesions with Medina X,1,1 classification requiring at least 2 stents~* Left main (≥50%) or proximal LAD (≥70%) lesion~* Calcified target lesion(s) requiring atherectomy~Exclusion Criteria:~* Under 18 years of age~* Contraindication to aspirin~* Contraindication to ticagrelor~* Planned surgery within 90 days~* Planned coronary revascularization (surgical or percutaneous) within 90 days~* Need for chronic oral anticoagulation~* Prior stroke~* Dialysis-dependent renal failure~* Active bleeding or extreme-risk for major bleeding (e.g. active peptic ulcer disease, gastrointestinal pathology with a raised risk for bleeding, malignancies with a raised risk for bleeding)~* Salvage PCI or STEMI presentation.~* Liver cirrhosis~* Life expectancy \< 1 year~* Unable or unwilling to provide informed consent~* Women of child bearing potential. Defined: a woman is considered potential (WOBCP) following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. a postmenopausal state is defined as no menses for 12 months without an alternative medical cause.~* Fibrinolytic therapy within 24 hours of index PCI~* Concomitant therapy with a strong cytochrome P-450 3A inhibitor or inducer~* Platelet count \< 100,000 mm3~* Requiring ongoing treatment with aspirin ≥ 325 mg daily

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin + Ticagrelor (Type: ACTIVE_COMPARATOR): enteric coated aspirin 81mg-100mg daily p.o. for 12 months and ticagrelor 90mg tablet bid for 12 months
- Placebo + Ticagrelor (Type: PLACEBO_COMPARATOR): placebo pill daily p.o. for 12 months - match for enteric coated aspirin 81mg-100mg and ticagrelor 90mg tablet bid for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).